Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509117 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT02509117 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 55 participants.
The verdict
NCT02509117, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
Interventions
- DRUG Placebo single dose
- DRUG PF-06751979 single ascending dose
- DRUG PF-06751979 multiple ascending dose
- DRUG Placebo multiple dose
- DRUG PF-06751979 multiple dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02509117
The ClinicalTrials.gov registry entry for NCT02509117 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo single dose is the first listed.
NCT02509117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02509117 about?
NCT02509117 is a clinical study titled "First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979". The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
What is the current status of trial NCT02509117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2015-07. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02509117?
The interventions under investigation include: Placebo single dose (DRUG), PF-06751979 single ascending dose (DRUG), PF-06751979 multiple ascending dose (DRUG), Placebo multiple dose (DRUG), PF-06751979 multiple dose (DRUG).
Who is sponsoring clinical trial NCT02509117?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.